| Medical and Health Sciences | Lifetime | 95 | US 52 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 652 | US 223 | 99.86 |
| Cardiology and Cardiovascular Medicine | Lifetime | 29 | US 21 | 99.98 |
| Surgery | Lifetime | 126 | US 64 | 99.89 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 134 | US 79 | 99.66 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 316 | US 175 | 99.05 |
| Internal Medicine | Lifetime | 216 | US 89 | 95.25 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 117 | US 59 | 99.44 |
| Surgery | 2021-2025 | 182 | US 72 | 98.93 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 162 | US 74 | 97.36 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 674 | US 153 | 85.07 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 860 | US 290 | 78.34 |
| Acute Myocardial Infarction Research | Lifetime | 16 | US 11 | 99.94 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 18 | US 9 | 99.88 |
| Cardiac Imaging and Diagnostics | Lifetime | 55 | US 34 | 99.88 |
| Cardiovascular Function and Risk Factors | Lifetime | 73 | US 53 | 99.84 |
| Lipoproteins and Cardiovascular Health | Lifetime | 51 | US 32 | 99.70 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 99 | US 45 | 99.66 |
| Coronary Interventions and Diagnostics | Lifetime | 92 | US 44 | 99.70 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 151 | US 60 | 99.51 |
| Heart Failure Treatment and Management | Lifetime | 105 | US 60 | 99.59 |
| Cardiac Ischemia and Reperfusion | Lifetime | 80 | US 44 | 99.22 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 189 | US 105 | 99.43 |
| Diabetes Treatment and Management | Lifetime | 154 | US 69 | 99.31 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 307 | US 146 | 99.10 |
| Cardiomyopathy and Myosin Studies | Lifetime | 194 | US 108 | 98.76 |
| Cardiac Arrhythmias and Treatments | Lifetime | 368 | US 188 | 98.97 |
| Health and Medical Research Impacts | Lifetime | 120 | US 67 | 96.58 |
| Cardiac Valve Diseases and Treatments | Lifetime | 966 | US 443 | 98.24 |
| Cardiac Structural Anomalies and Repair | Lifetime | 681 | US 403 | 98.13 |
| Cardiac pacing and defibrillation studies | Lifetime | 697 | US 358 | 98.00 |
| Heart Rate Variability and Autonomic Control | Lifetime | 911 | US 409 | 97.39 |
| Cardiac Fibrosis and Remodeling | Lifetime | 278 | US 108 | 96.05 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 900 | US 365 | 97.22 |
| Cardiovascular Effects of Exercise | Lifetime | 803 | US 340 | 95.96 |
| Potassium and Related Disorders | Lifetime | 216 | US 109 | 95.92 |
| Healthcare cost, quality, practices | Lifetime | 990 | US 527 | 90.62 |
| GDF15 and Related Biomarkers | Lifetime | 990 | US 299 | 72.70 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 148 | US 72 | 98.96 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 72 | US 34 | 98.13 |
| Acute Myocardial Infarction Research | 2021-2025 | 159 | US 48 | 97.61 |
| Heart Failure Treatment and Management | 2021-2025 | 170 | US 67 | 98.00 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 110 | US 52 | 97.04 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 466 | US 120 | 96.67 |
| Diabetes Treatment and Management | 2021-2025 | 412 | US 145 | 95.60 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 269 | US 73 | 93.78 |
| Congenital Heart Disease Studies | 2021-2025 | 829 | US 377 | 89.14 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 846 | US 167 | 84.15 |
| Cardiovascular Effects of Exercise | 2021-2025 | 846 | US 225 | 83.27 |
| Potassium and Related Disorders | 2021-2025 | 367 | US 143 | 73.42 |
| GDF15 and Related Biomarkers | 2021-2025 | 788 | US 199 | 47.56 |
